AMPH
Price
$28.60Alerts
Change
-$0.46 (-1.58%)
Updated
Nov 11 closing price
Capitalization
1.21B
112 days until earnings call
Intraday BUY SELL Signals
ZTS
Price
$82.57Alerts
Change
+$0.11 (+0.13%)
Updated
Nov 11 closing price
Capitalization
32.81B
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs ZTS

AMPH vs ZTS Comparison Chart in %
View a ticker or compare two or three
VS
AMPH vs. ZTS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Buy and ZTS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AMPH with price predictions
Nov 11, 2026

AMPH in +6.22% Uptrend, growing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AMPH advanced for three days, in 254 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AMPH as a result. In 59 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for AMPH just turned positive on October 30, 2026. Looking at past instances where AMPH's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The 10-day RSI Indicator for AMPH moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 27 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 69 cases where AMPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

AMPH broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AMPH entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.578) is normal, around the industry mean (6.379). P/E Ratio (16.374) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.640) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.522) is also within normal values, averaging (183.387).

The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for ZTS with price predictions
Nov 11, 2026

Momentum Indicator for ZTS turns positive, indicating new upward trend

ZTS saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 49 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 54%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

ZTS moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 38%.

Following a +0.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 145 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

The Aroon Indicator entered an Uptrend today. In 92 of 182 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.

Bearish Trend Analysis

The 10-day RSI Indicator for ZTS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 11 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 62 cases where ZTS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.

The Moving Average Convergence Divergence Histogram (MACD) for ZTS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

ZTS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ZTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.422) is normal, around the industry mean (6.379). P/E Ratio (12.953) is within average values for comparable stocks, (0.548). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.202). Dividend Yield (0.027) settles around the average of (0.062) among similar stocks. P/S Ratio (3.299) is also within normal values, averaging (183.387).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
AMPH vs ZTS: Fundamental Ratings
AMPH
ZTS
OUTLOOK RATING
1..100
2831
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
6918
PRICE GROWTH RATING
1..100
3646
P/E GROWTH RATING
1..100
1384
SEASONALITY SCORE
1..100
421

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMPH's Valuation (57) in the Pharmaceuticals Other industry is in the same range as ZTS (86) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to ZTS’s over the last 12 months.

AMPH's Profit vs Risk Rating (86) in the Pharmaceuticals Other industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's SMR Rating (18) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMPH (69) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew somewhat faster than AMPH’s over the last 12 months.

AMPH's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as ZTS (46) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to ZTS’s over the last 12 months.

AMPH's P/E Growth Rating (13) in the Pharmaceuticals Other industry is significantly better than the same rating for ZTS (84) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHZTS
RSI
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
62%
Bearish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
54%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
49%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 1 day ago
51%
Declines
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 6 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
63%
Bullish Trend 1 day ago
51%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AMPH: $28.60 vs. ZTS: $82.46)
Brand notoriety: AMPH: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 93% vs. ZTS: 106%
Market capitalization -- AMPH: $1.21B vs. ZTS: $32.81B
AMPH [@Pharmaceuticals: Generic] is valued at $1.21B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $32.81B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 1 FA rating(s) are green while ZTS’s FA Score has 1 green FA rating(s).

  • AMPH’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, AMPH is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 6 bullish TA indicator(s).

  • AMPH’s TA Score: 3 bullish, 5 bearish.
  • ZTS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than AMPH.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а +2.07% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -0.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.

Reported Earning Dates

AMPH is expected to report earnings on Mar 04, 2027.

ZTS is expected to report earnings on Feb 16, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.13% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+0.13%
PAHC - ZTS
58%
Loosely correlated
+1.47%
ELAN - ZTS
45%
Loosely correlated
-1.05%
PBH - ZTS
35%
Loosely correlated
-1.78%
SNDL - ZTS
33%
Loosely correlated
+2.16%
AMPH - ZTS
32%
Poorly correlated
-1.58%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ERIE272.180.09
+0.03%
Erie Indemnity Company
ADXN2.96N/A
N/A
Addex Therapeutics Ltd
SEER1.59-0.02
-1.24%
Seer
ATHM21.66-0.80
-3.56%
Autohome
HYLN2.78-0.21
-7.02%
Hyliion Holdings Corp